Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124390832 | 12439083 | 2 | F | 20130603 | 20160627 | 20160606 | 20160707 | EXP | JP-009507513-1606JPN002451 | MERCK | 1.00 | YR | F | Y | 10.40000 | KG | 20160707 | OT | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124390832 | 12439083 | 1 | PS | TEMODAL | TEMOZOLOMIDE | 1 | Intravenous (not otherwise specified) | 30 MG, QD | 150 | MG | 22277 | 30 | MG | SOLUTION FOR INJECTION | QD | ||||
| 124390832 | 12439083 | 2 | SS | TEMODAL | TEMOZOLOMIDE | 1 | Intravenous (not otherwise specified) | 46 MG, QD | 150 | MG | 22277 | 46 | MG | SOLUTION FOR INJECTION | QD | ||||
| 124390832 | 12439083 | 3 | SS | TEMODAL | TEMOZOLOMIDE | 1 | Intravenous (not otherwise specified) | 50 MG, QD | 150 | MG | 22277 | 50 | MG | SOLUTION FOR INJECTION | QD | ||||
| 124390832 | 12439083 | 4 | SS | TEMODAL | TEMOZOLOMIDE | 1 | Intravenous (not otherwise specified) | 50 MG, QD | 150 | MG | 22277 | 50 | MG | SOLUTION FOR INJECTION | QD | ||||
| 124390832 | 12439083 | 5 | SS | TEMODAL | TEMOZOLOMIDE | 1 | Intravenous (not otherwise specified) | 50 MG, QD | 150 | MG | 22277 | 50 | MG | SOLUTION FOR INJECTION | QD | ||||
| 124390832 | 12439083 | 6 | SS | IRINOTECAN HYDROCHLORIDE. | IRINOTECAN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | 6.4 MG, QD | 32 | MG | U | 0 | 6.4 | MG | INJECTION | QD | |||
| 124390832 | 12439083 | 7 | SS | IRINOTECAN HYDROCHLORIDE. | IRINOTECAN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | 9 MG, QD | 32 | MG | U | 0 | 9 | MG | INJECTION | QD | |||
| 124390832 | 12439083 | 8 | SS | IRINOTECAN HYDROCHLORIDE. | IRINOTECAN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | 10 MG, QD | 32 | MG | U | 0 | 10 | MG | INJECTION | QD | |||
| 124390832 | 12439083 | 9 | SS | IRINOTECAN HYDROCHLORIDE. | IRINOTECAN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | 10 MG, QD | 32 | MG | U | 0 | 10 | MG | INJECTION | QD | |||
| 124390832 | 12439083 | 10 | SS | IRINOTECAN HYDROCHLORIDE. | IRINOTECAN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | 10 MG, QD | 32 | MG | U | 0 | 10 | MG | INJECTION | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124390832 | 12439083 | 1 | Neuroblastoma |
| 124390832 | 12439083 | 6 | Neuroblastoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124390832 | 12439083 | HO |
| 124390832 | 12439083 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124390832 | 12439083 | Febrile neutropenia | |
| 124390832 | 12439083 | Neutropenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124390832 | 12439083 | 1 | 20130319 | 20130323 | 0 | |
| 124390832 | 12439083 | 2 | 20130416 | 20130420 | 0 | |
| 124390832 | 12439083 | 3 | 20130514 | 20130518 | 0 | |
| 124390832 | 12439083 | 4 | 20130618 | 20130622 | 0 | |
| 124390832 | 12439083 | 5 | 20130716 | 20130720 | 0 | |
| 124390832 | 12439083 | 6 | 20130319 | 20130323 | 0 | |
| 124390832 | 12439083 | 7 | 20130416 | 20130420 | 0 | |
| 124390832 | 12439083 | 8 | 20130514 | 20130518 | 0 | |
| 124390832 | 12439083 | 9 | 20130618 | 20130622 | 0 | |
| 124390832 | 12439083 | 10 | 20130716 | 20130720 | 0 |